{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:24:02Z","timestamp":1787664242736,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"crossref","award":["JP23K07359"],"award-info":[{"award-number":["JP23K07359"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"TOYOAKI SCHOLARSHIP FOUNDATION","award":["TOYOAKI SCHOLARSHIP FOUNDATION"],"award-info":[{"award-number":["TOYOAKI SCHOLARSHIP FOUNDATION"]}]},{"name":"The Nitto Foundation","award":["The Nitto Foundation"],"award-info":[{"award-number":["The Nitto Foundation"]}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["Takeda Science Foundation"],"award-info":[{"award-number":["Takeda Science Foundation"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","award":["Uehara Memorial Foundation"],"award-info":[{"award-number":["Uehara Memorial Foundation"]}],"id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grant-in Aid for Research in Nagoya City University","award":["2522103"],"award-info":[{"award-number":["2522103"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10147-026-03114-y","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T17:31:02Z","timestamp":1782581462000},"page":"1995-2005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis"],"prefix":"10.1007","volume":"31","author":[{"given":"Takanori","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Narahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoto","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Mizoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Uojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuko","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"3114_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"3114_CR2","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park JW, Chen M, Colombo M et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 35:2155\u20132166","journal-title":"Liver Int"},{"key":"3114_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Akinyemiju T, Abera S, Ahmed M et al (2017) The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 3:1683\u20131691","journal-title":"JAMA Oncol"},{"key":"3114_CR4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905","journal-title":"N Engl J Med"},{"key":"3114_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M et al (2022) Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76:862\u2013873","journal-title":"J Hepatol"},{"key":"3114_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/carcin\/bgh332","volume":"26","author":"K Nakagawa","year":"2005","unstructured":"Nakagawa K, Kawaura A, Kato S et al (2005) 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 26:429\u2013440","journal-title":"Carcinogenesis"},{"key":"3114_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0038-9","volume":"50","author":"SM Jeon","year":"2018","unstructured":"Jeon SM, Shin EA (2018) Exploring vitamin D metabolism and function in cancer. Exp Mol Med 50:1\u201314","journal-title":"Exp Mol Med"},{"key":"3114_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.semcancer.2020.05.018","volume":"79","author":"C Carlberg","year":"2022","unstructured":"Carlberg C, Mu\u00f1oz A (2022) An update on vitamin D signaling and cancer. Semin Cancer Biol 79:217\u2013230","journal-title":"Semin Cancer Biol"},{"key":"3114_CR9","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/cncr.34718","volume":"129","author":"\u0141 Galus","year":"2023","unstructured":"Galus \u0141, Michalak M, Lorenz M et al (2023) Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD-1 therapy. Cancer 129:2047\u20132055","journal-title":"Cancer"},{"key":"3114_CR10","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s00262-023-03522-3","volume":"72","author":"M Bersanelli","year":"2023","unstructured":"Bersanelli M, Cortellini A, Leonetti A et al (2023) Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study. Cancer Immunol Immunother 72:3707\u20133716","journal-title":"Cancer Immunol Immunother"},{"key":"3114_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.105524","volume":"197","author":"Q Wu","year":"2020","unstructured":"Wu Q, Wang X, Pham K et al (2020) Enhancement of sorafenib-mediated death of hepatocellular carcinoma cells by carnosic acid and vitamin D2 analog combination. J Steroid Biochem Mol Biol 197:105524","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3114_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Br\u00fa C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329\u2013338","journal-title":"Semin Liver Dis"},{"key":"3114_CR13","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/MEG.0000000000001405","volume":"31","author":"YM Hong","year":"2019","unstructured":"Hong YM, Yoon KT, Hwang TH et al (2019) Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 31:1250\u20131255","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3114_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550\u2013558","journal-title":"J Clin Oncol"},{"key":"3114_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000488778","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Tsuji K et al (2019) Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis. Liver Cancer 8:121\u2013129","journal-title":"Liver Cancer"},{"key":"3114_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"3114_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"3114_CR18","doi-asserted-by":"publisher","DOI":"10.1159\/000546515.1-10","author":"T Suzuki","year":"2025","unstructured":"Suzuki T, Matsuura K, Kato D et al (2025) Number of tumors stratifies the therapeutic response to atezolizumab plus bevacizumab therapy in barcelona clinic liver cancer stage B unresectable hepatocellular carcinoma: a multicenter analysis. Oncology. https:\/\/doi.org\/10.1159\/000546515.1-10","journal-title":"Oncology"},{"key":"3114_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/nu14030473","author":"S Giannini","year":"2022","unstructured":"Giannini S, Giusti A, Minisola S et al (2022) The immunologic profile of vitamin D and its role in different immune-mediated diseases: an expert opinion. Nutrients. https:\/\/doi.org\/10.3390\/nu14030473","journal-title":"Nutrients"},{"key":"3114_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01635581.2020.1797127","volume":"73","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Jiang X, Li X et al (2021) Serum vitamin D levels and risk of liver cancer: a systematic review and dose-response meta-analysis of cohort studies. Nutr Cancer 73:1\u20139","journal-title":"Nutr Cancer"},{"key":"3114_CR21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1500409","volume":"373","author":"JA Baron","year":"2015","unstructured":"Baron JA, Barry EL, Mott LA et al (2015) A trial of calcium and vitamin D for the prevention of colorectal adenomas. N Engl J Med 373:1519\u20131530","journal-title":"N Engl J Med"},{"key":"3114_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.31557\/APJCP.2021.22.4.991","volume":"22","author":"Z Yi","year":"2021","unstructured":"Yi Z, Wang L, Tu X (2021) Effect of vitamin D deficiency on liver cancer risk: a systematic review and meta-analysis. Asian Pac J Cancer Prev 22:991\u2013997","journal-title":"Asian Pac J Cancer Prev"},{"key":"3114_CR23","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.3390\/nu5072502","volume":"5","author":"B Prietl","year":"2013","unstructured":"Prietl B, Treiber G, Pieber TR et al (2013) Vitamin D and immune function. Nutrients 5:2502\u20132521","journal-title":"Nutrients"},{"key":"3114_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003477","author":"P Li","year":"2022","unstructured":"Li P, Zhu X, Cao G et al (2022) 1\u03b1,25(OH)2D3 reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003477","journal-title":"J Immunother Cancer"},{"key":"3114_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.105557","volume":"198","author":"JC Fleet","year":"2020","unstructured":"Fleet JC, Burcham GN, Calvert RD et al (2020) 1\u03b1, 25 Dihydroxyvitamin D (1,25(OH)2D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC). J Steroid Biochem Mol Biol 198:105557","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3114_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3390\/cancers17030495","volume":"17","author":"A Jain","year":"2025","unstructured":"Jain A, Stebbing J (2025) The relationship between response rate and survival benefits in randomized immunotherapy studies. Cancers (Basel) 17:495","journal-title":"Cancers (Basel)"},{"key":"3114_CR27","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s12072-022-10392-x","volume":"16","author":"CT Chen","year":"2022","unstructured":"Chen CT, Feng YH, Yen CJ et al (2022) Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatol Int 16:1199\u20131207","journal-title":"Hepatol Int"},{"key":"3114_CR28","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/hepr.13485","volume":"50","author":"T Okubo","year":"2020","unstructured":"Okubo T, Atsukawa M, Tsubota A et al (2020) Relationship between serum vitamin D level and sarcopenia in chronic liver disease. Hepatol Res 50:588\u2013597","journal-title":"Hepatol Res"},{"key":"3114_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0299313","volume":"19","author":"T Okubo","year":"2024","unstructured":"Okubo T, Atsukawa M, Tsubota A et al (2024) Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease. PLoS ONE 19:e0299313","journal-title":"PLoS ONE"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03114-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03114-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03114-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:08:36Z","timestamp":1787663316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03114-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3114"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03114-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yasuhito Tanaka: Research funding from AbbVie GK. OTSUKA Pharmaceutical Co., Ltd, FUJIREBIO Inc, Sysmex Corp GlaxoSmithKline PLC., Gilead Sciences, Inc., AstraZeneca and speaker\u2019s fees from AbbVie GK., Gilead Sciences, Inc, Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Holdings Co., Ltd., GlaxoSmithKline PLC., AstraZeneca, Eisai, HU frontier. Takako Inoue: Research funding from Fujirebio Incorporation, and Sysmex Corporation. The other authors have no conflict of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with approval from the Institutional Review Boards of Nagoya City University (approval no. 60-21-0065) and Kumamoto University Hospital (approval no. 2265), in accordance with the Declaration of Helsinki. Registry and registration Nos.: 60-21-0065 and 2265.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}